Pharmacologic class (EPC) · 4 drug pages

Interleukin-17A antagonist: adverse event reports filed with FDA

190,442 reports list a drug in this class as a suspect or interacting product, 2014–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

190,442
reports across the class: 0.9% of all reports; 8,527
reports, 12 months to June 2026: 12,926 in the 12 months before; 36%
marked serious by the reporter: 57.4% across all reports; 4
drugs with a page: brand and generic names counted separately

Interleukin-17A antagonist is a pharmacologic class (an FDA Established Pharmacologic Class) with 4 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 190,442 adverse event reports received by FDA, 0.9% of the database, from January 2014 to June 2026.

8,527 reports arrived in the 12 months to June 2026, down 34% from 12,926 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 36% of the class's reports are marked serious, 4.6% record death among the outcomes and 12.4% record hospitalisation, as reported.

Across the class the reactions recorded most often are drug ineffective (16.4%), psoriasis (13.3%) and pain (8.8%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
CosentyxSecukinumab	brand	151,295	5,952	38%	Drug ineffective
TaltzIxekizumab	brand	33,889	1,851	17.9%	Injection site pain
Secukinumab	generic	4,206	558	96.6%	Drug ineffective
Ixekizumab	generic	1,052	166	83.7%	Drug ineffective

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Drug ineffectivethe medicine did not work as expected16.4%31,152
Psoriasispsoriasis, a skin condition13.3%25,339
Painpain, site not specified8.8%16,752
Arthralgiajoint pain8%15,204
Fatiguetiredness5.6%10,637
Psoriatic arthropathy5.4%10,225
Pruritusitching5.2%9,853
Malaisegeneral feeling of being unwell5.1%9,682
Rashskin rash5%9,485
Condition aggravatedthe condition being treated got worse4.5%8,568
Diarrhoealoose or frequent stools4.4%8,344
Nasopharyngitisa cold4.3%8,210
Headachehead pain3.9%7,379
Pain in extremitypain in an arm or leg3.9%7,375
Injection site painpain where the injection was given3.8%7,304
Off label useused for a purpose or in a way not on the label3.6%6,904
Nauseafeeling sick3.5%6,671
Joint swellinga swollen joint3.4%6,518
Musculoskeletal stiffnessstiffness in muscles or joints3.3%6,299
Incorrect dose administeredthe wrong dose was given3%5,709
Pyrexiafever3%5,654
Peripheral swellingswelling of the arms or legs2.9%5,580
Product dose omission issuea dose was missed2.9%5,570
Inappropriate schedule of product administrationthe product was taken at the wrong times2.9%5,519
Pneumonialung infection2.8%5,343

Solid bar: share of all class reports. Hollow bar: the median share across the 4 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death4.6%8,794

Life-threatening4%7,649

Hospitalisation (initial or prolonged)12.4%23,665

Disability3.8%7,251

Congenital anomaly1.6%3,097

Other serious27.9%53,132

Not serious64%121,941

Patient age

Under 20%94

2 to 110.1%187

12 to 170.3%556

18 to 4413.2%25,120

45 to 6421.1%40,206

65 to 746%11,338

75 and over2.1%4,064

Age not given57.2%108,877

Who reported

Physician13.4%25,499

Pharmacist3.1%5,928

Other health professional23.9%45,595

Lawyer0%8

Consumer or non-health professional57.4%109,345

Not given2.1%4,067

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Interleukin-17A antagonist reports

Which drugs are in the Interleukin-17A antagonist class on this site?

Cosentyx, Taltz, Secukinumab and Ixekizumab. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

190,442 reports through June 2026, 8,527 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

drug ineffective (16.4%), psoriasis (13.3%), pain (8.8%), arthralgia (8%) and fatigue (5.6%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.